ArticleMicrobial cell factories2024
High-efficiency production of plant-derived pigment dopaxanthin in Escherichia coli by combination engineering.
Article in Microbial cell factories, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundDopaxanthin is a natural pigment betaxanthins family member with the highest antioxidant and free radical scavenging activities. However, its relatively low content in plants limited the wide range of applications. Cost-efficient microbial production, therefore, showed an attractive alternative.
resultsHere, an Escherichia coli strain equipped with the de novo biosynthetic pathway for hyperproducing dopaxanthin was constructed by combining metabolic engineering and protein engineering. Firstly, a high-performance rate-limiting levodopa 4,5-dioxygenase (DODA) was mined and characterized based on sequence similarity searching followed by whole-cell catalysis and de novo synthesis strategy. Then, the catalytic efficiency of DODA was increased 34 times with directed evolution. The mutated DODA significantly facilitated the production of dopaxanthin, with an increase of 40.17% in plasmid expression and 64.11% in genome expression, respectively. Finally, through connecting the blocked pathway from 3-dehydroshikimate to levodopa (L-DOPAOPA) and enhancing the expression level of DODA, a titer of dopaxanthin of 22.87 g/L was achieved from glucose as feedstock, which is 286 times higher than that in the previous report.
conclusionThis work not only established a promising platform for the environmentally friendly production of dopaxanthin but also laid a foundation for the commercialization of other betalain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.